# Biomarker Effects of ALZ-801 in APOE4 Carriers With Early Alzheimer's Disease

> **NCT04693520** · PHASE2 · COMPLETED · sponsor: **Alzheon Inc.** · enrollment: 84 (actual)

## Conditions studied

- Early Alzheimer's Disease

## Interventions

- **DRUG:** ALZ-801

## Key facts

- **NCT ID:** NCT04693520
- **Lead sponsor:** Alzheon Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-30
- **Primary completion:** 2023-06-20
- **Final completion:** 2025-07-16
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04693520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04693520, "Biomarker Effects of ALZ-801 in APOE4 Carriers With Early Alzheimer's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04693520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*